GSA Capital Partners’s Cue Biopharma CUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-117,262
| Closed | -$107K | – | 1803 |
|
|
2025
Q1 | $107K | Sell |
117,262
-32,536
| -22% | -$29.7K | 0.01% | 1488 |
|
|
2024
Q4 | $163K | Sell |
149,798
-141,865
| -49% | -$154K | 0.01% | 1459 |
|
|
2024
Q3 | $221K | Buy |
291,663
+14,104
| +5% | +$10.7K | 0.02% | 1376 |
|
|
2024
Q2 | $344K | Buy |
277,559
+68,459
| +33% | +$84.8K | 0.02% | 1193 |
|
|
2024
Q1 | $395K | Buy |
209,100
+195,148
| +1,399% | +$369K | 0.03% | 1045 |
|
|
2023
Q4 | $37K | Buy |
+13,952
| New | +$37K | ﹤0.01% | 1426 |
|
|
2023
Q3 | – | Sell |
-18,269
| Closed | -$67K | – | 1560 |
|
|
2023
Q2 | $67K | Sell |
18,269
-54,842
| -75% | -$201K | 0.01% | 1408 |
|
|
2023
Q1 | $261K | Sell |
73,111
-115,197
| -61% | -$411K | 0.03% | 1110 |
|
|
2022
Q4 | $537K | Sell |
188,308
-27,942
| -13% | -$79.7K | 0.07% | 561 |
|
|
2022
Q3 | $482K | Buy |
216,250
+86,584
| +67% | +$193K | 0.06% | 592 |
|
|
2022
Q2 | $323K | Buy |
129,666
+33,103
| +34% | +$82.5K | 0.05% | 776 |
|
|
2022
Q1 | $471K | Sell |
96,563
-3,253
| -3% | -$15.9K | 0.06% | 575 |
|
|
2021
Q4 | $1.13M | Sell |
99,816
-21,911
| -18% | -$248K | 0.14% | 151 |
|
|
2021
Q3 | $1.77M | Buy |
121,727
+93,331
| +329% | +$1.36M | 0.18% | 88 |
|
|
2021
Q2 | $331K | Buy |
28,396
+15,730
| +124% | +$183K | 0.04% | 890 |
|
|
2021
Q1 | $155K | Sell |
12,666
-51,631
| -80% | -$632K | 0.03% | 951 |
|
|
2020
Q4 | $804K | Buy |
64,297
+19,496
| +44% | +$244K | 0.13% | 196 |
|
|
2020
Q3 | $674K | Buy |
+44,801
| New | +$674K | 0.11% | 249 |
|